Asia
Biocon Ltd, Asia’s premier biopharmaceuticals company, Biocon Ltd announced that it’s subsidiary in Malaysia, Biocon Sdn.
Biopharma companies large and small are involved in numerous clinical trials. Here’s a look at some of the top stories from last week.
Singapore molecular diagnostics groups INEX Innovations Exchange Pte. Ltd. (INEX) and Nova Satra Dx Pte. Ltd. (Nova Satra) announced the merger of the two companies to create INEX INNOVATE.
Companies from across the globe provide updates on their business and pipelines.
Over a 12-week course of treatment, Teva said fremanezumab provided patients with statistically significant reductions in monthly average number of migraine days. The results of the study were published in Lancet.
WuXi Biologics (Cayman) Inc. announced its unaudited interim results for the six months ended June 30, 2019.
Xylonix announced it has signed a Memorandum of Understanding (MOU) with BioGemex to jointly develop a new pre-treatment point-of-care diagnostic, XDX-01, to better predict a patient’s response to T-cell mediated cancer immunotherapies in solid tumors.
Label-free, 3-D holotomography imaging enables researchers to observe morphological and chemical alterations of host cells without transfection or dye staining
D&D Pharmatech is the parent company of U.S.-based Neuraly, Precision Molecular and Theraly Fibrosis. All three are spinouts from Johns Hopkins School of Medicine.
Great Bay Bio, a leading AI biotechnology company dedicated to big data-driven CMC development of innovative biologics, is pleased to announce the establishment of its 3D Advisory Board.
PRESS RELEASES